In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Non-animal tox tests "make sense" as screening tool for in vivo tests, FDA says.

This article was originally published in The Rose Sheet

Executive Summary

NON-ANIMAL TOX TESTS MORE APPROPRIATE AS SCREENING TOOL FOR CHEMICALS, FDA said, as federal agencies attempt to reduce the use of animal testing. The agency is concerned, however, with the replacement of all in vivo trials with in vitro assays. Commenting on legislation that would ask all agencies, including FDA, to adopt in vitro alternative testing methods recommended by the Inter-Agency Coordinating Committee for the Validation of Alternative Methods (ICCVAM), FDA said it supports the development of non-animal toxicological tests but suggested their use might "make sense" as a first-tier screening mechanism that then could be used to determine the necessity of animal tests. HR 3946, the ICCVAM Authorization Act, was introduced May 22 by Rep. Tom Lantos (D-Calif.) with 36 co-sponsors ("The Rose Sheet" June 1, p. 7).

Latest Headlines
See All
UsernamePublicRestriction

Register

RS005490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel